Nicotinell Fruit 4 mg nicotine gum

Nicotinell is a prominent brand in the Nicotine Replacement Therapy (NRT) sector, originally developed in Switzerland by the pharmaceutical company Ciba-Geigy (which later became part of Novartis). The product shown is a 4 mg medicated fruit-flavored gum designed to help individuals manage nicotine cravings and withdrawal symptoms during smoking cessation.

Historically, the brand was a key part of the Novartis Consumer Health portfolio before transitioning to the GSK-Pfizer consumer healthcare joint venture, known as Haleon. In a significant industry move completed in late 2024, Haleon sold its global NRT business (excluding the United States) to Dr. Reddy's Laboratories, an Indian multinational pharmaceutical company. Manufacturing for Nicotinell products occurs across several specialized facilities globally, including sites in Switzerland and Sweden, to serve its extensive international market presence in over 30 countries.